Natalizumab Re-Initiation of Dosing
NCT00306592
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
404
Enrollment
INDUSTRY
Sponsor class
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BIOLOGICAL:
BG00002 (natalizumab)
Sponsor
Biogen
Collaborators
[object Object]